
Olmesartan Medoxomil (20mg) + Chlorthalidone (12.5mg)
Active composition
+1 more active ingredient
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmibite CT 20 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively inhibits the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and reduction of blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, thereby reducing plasma volume and peripheral vascular resistance. This combination is indicated for the treatment of hypertension, providing additive blood pressure-lowering effects through complementary mechanisms. Olmibite CT 20 Tablet helps in controlling high blood pressure, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. It is typically administered once daily, with or without food, and dosage adjustments should be individualized based on patient response and tolerability. Caution is advised in patients with renal impairment, electrolyte imbalances, or hypersensitivity to sulfonamide-derived drugs. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy. Olmibite CT 20 Tablet should be used under medical supervision.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmibite CT 20 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmibite CT 20 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmibite CT 20 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmibite CT 20 Tablet may be needed. Please consult your doctor. Use of Olmibite CT 20 Tablet is not recommended in these patients.
Exercise Caution
Olmibite CT 20 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Olmibite CT 20 Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmibite CT 20 Tablet may be needed. Please consult your doctor. Use of Olmibite CT 20 Tablet is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Olmibite CT 20 Tablet

Olmesartan Medoxomil (20mg) + Chlorthalidone (12.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Olmesartan Medoxomil blocks angiotensin II receptors, preventing vasoconstriction and lowering blood pressure.
Medical applications
Olmibite CT 20 Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively inhibits the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and reduction of blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, thereby reducing plasma volume and peripheral vascular resistance. This combination is indicated for the treatment of hypertension, providing additive blood pressure-lowering effects through complementary mechanisms. Olmibite CT 20 Tablet helps in controlling high blood pressure, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. It is typically administered once daily, with or without food, and dosage adjustments should be individualized based on patient response and tolerability. Caution is advised in patients with renal impairment, electrolyte imbalances, or hypersensitivity to sulfonamide-derived drugs. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy. Olmibite CT 20 Tablet should be used under medical supervision.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Olmibite CT 20 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Olmibite CT 20 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Olmibite CT 20 Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Olmibite CT 20 Tablet may be needed. Please consult your doctor. Use of Olmibite CT 20 Tablet is not recommended in these patients.
Exercise Caution
Olmibite CT 20 Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Olmibite CT 20 Tablet should be used with caution in patients with liver disease. Dose adjustment of Olmibite CT 20 Tablet may be needed. Please consult your doctor. Use of Olmibite CT 20 Tablet is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Olmibite CT 20 Tablet















